| C.E.R.A. dose group (μg/kg QW) | C.E.R.A. dose group (μg/kg Q3W) | ||||
---|---|---|---|---|---|---|
 | 0.7 | 1.4 | 2.1 | 2.1 | 4.2 | 6.3 |
Number of patients randomized | 36 | 37 | 36 | 37 | 37 | 35 |
Sex, n, (%) | Â | Â | Â | Â | Â | Â |
   Male | 23 (64) | 22 (59) | 26 (72) | 22 (59) | 20 (54) | 28 (80) |
   Female | 13 (36) | 15 (41) | 10 (28) | 15 (41) | 17 (46) | 7 (20) |
Age, y (range) | 66 (52–80) | 65 (41–83) | 66 (50–83) | 63 (41–91) | 63 (24–84) | 64 (33–81) |
Body weight, kg (range) | 71 (41–127) | 70 (39–102) | 71 (41–91) | 66 (36–90) | 66 (39–89) | 72 (47–100) |
Disease stage, n, (%) | Â | Â | Â | Â | Â | Â |
   IIIB | 9 (25) | 10 (27) | 9 (26) | 13 (38) | 11 (30) | 4 (12) |
   IV | 27 (75) | 27 (73) | 26 (74) | 21 (62) | 26 (70) | 30 (88) |
Previous treatment before study entry, n, (%) | Â | Â | Â | Â | Â | Â |
   Chemotherapy | 32 (89) | 35 (95) | 30 (86) | 33 (97) | 34 (92) | 31 (91) |
   Surgery | 13 (36) | 10 (27) | 7 (20) | 8 (24) | 11 (30) | 9 (26) |
   Radiotherapy | 10 (28) | 10 (27) | 6 (17) | 8 (24) | 14 (38) | 10 (29) |
   ESA | 0 | 2 (5) | 1 (3) | 0 | 1 (3) | 2 (6) |
Hb level, g/dL (range) | 10.2 (7.1–13.9) | 10.2 (8.1–12.8) | 10.3 (3.5–12.7) | 10.4 (6.8–13.3) | 10.1 (8.0–12.9) | 10.6 (8.0–14.0) |
Serum ferritin level, ng/mL (range) | 350 (55–2188) | 439 (48–1231) | 285 (65–1403) | 502 (92–1718) | 472 (90–1225) | 507 (79–1561) |